Havana, April 11 (RHC) The British group The Lancet Discovery Science published in its journal Clinical Medicine a scientific article on the Cuban Abdala vaccine, which shows that it is safe, well tolerated and induces a powerful immune response against SARS. -CoV-2.
The results obtained by these researchers – who publish early evidence on new methods capable of improving health in the world – support the work of Cuban scientists and the high efficacy demonstrated by the drug at the national level (92.28%).
Abdala, will present his dossier to the World Health Organization (WHO) and start the process of international recognition, it is produced in the Industrial Technological CIGB-Mariel, the most modern in Cuba and one of the most advanced in Latin America and the Caribbean , as understood.
Additionally, the Cuban anti-Covid-19 immunogen Soberana 02, from the Finlay Vaccine Institute, was recognized a few days ago by the German journal Toxicology, which highlighted its safety after a preclinical study that evaluated variables such as pain, inflammation and immune response.
Along with Soberana Plus, Cuba already has three immunizers against SARS-CoV-2 and two other candidates under study (Mambisa and Soberana 01).
To date, 35 million 519 thousand 808 doses of national products have been administered and nine million 922 thousand 576 people have the complete vaccination schedule, 89.6% of the citizenry.
The country leads the list in relation to the highest number of doses of immunizations per 100 inhabitants, according to the Oxford University statistics site, Our World in Data.